Denosumab discontinuation: COVID-19 pandemic and beyond

Area of Science:

• Osteoporosis and Bone Metabolism
• Pharmacology and Therapeutics
• Public Health and Epidemiology

Background:

• The COVID-19 pandemic significantly disrupted global healthcare systems, particularly affecting patients with chronic diseases.
• Studies indicate an initial decrease in timely denosumab administration during the pandemic's onset.
• Denosumab discontinuation can occur in various clinical scenarios beyond pandemic-related emergencies.

Purpose of the Study:

• To highlight the impact of the COVID-19 pandemic on denosumab therapy.
• To emphasize the need for strategic management of denosumab discontinuation.
• To outline approaches for optimizing patient care and minimizing risks associated with treatment interruption.

Main Methods:

• Review of existing literature on denosumab therapy disruptions.
• Analysis of clinical scenarios leading to denosumab discontinuation.
• Development of a framework for managing treatment interruptions.

Main Results:

• The pandemic caused immediate disruptions in denosumab treatment schedules.
• Non-pandemic related reasons for discontinuation also necessitate careful management.
• A proactive strategy is essential for continuity of care.

Conclusions:

• Effective management strategies are vital for denosumab therapy, especially during healthcare crises.
• Proactive planning can mitigate risks associated with denosumab discontinuation.
• Ensuring consistent patient care requires adaptable treatment protocols.